Prevalence and clinical implications of cyclin D1 expression in diffuse large B‐cell lymphoma (DLBCL) treated with immunochemotherapy: A report from the International DLBCL Rituximab‐CHOP Consortium Program

Cyclin D1 expression has been reported in a subset of patients with diffuse large B‐cell leukemia (DLBCL), but studies have been few and generally small, and they have demonstrated no obvious clinical implications attributable to cyclin D1 expression.

[1]  K. Seitz.  Mantelzell-Lymphom , 2016, Z Ultraschall in der Medizin.

[2]  C. Ruiz,et al.  Clinical, Morphologic, Phenotypic, and Genetic Evidence of Cyclin D1-positive Diffuse Large B-cell Lymphomas With CYCLIN D1 Gene Rearrangements , 2014, The American journal of surgical pathology.

[3]  W. Choi,et al.  CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. , 2013, Blood.

[4]  W. Choi,et al.  Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study , 2013, Haematologica.

[5]  T. Witzig,et al.  Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP. , 2012, Blood.

[6]  W. Choi,et al.  Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. , 2012, Blood.

[7]  L. Colomo,et al.  SOX11 is useful in differentiating cyclin D1‐positive diffuse large B‐cell lymphoma from mantle cell lymphoma , 2012, Histopathology.

[8]  K. Dybkær,et al.  Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study , 2012, Leukemia.

[9]  F. Izquierdo,et al.  CD5(-) diffuse large B-cell lymphoma with peculiar cyclin D1+ phenotype. Pathologic and molecular characterization of a single case. , 2012, Human pathology.

[10]  M. Paulli,et al.  CD5(-) diffuse large B-cell lymphoma with peculiar cyclin D1+ phenotype. Pathologic and molecular characterization of a single case. , 2011, Human pathology.

[11]  E. Jaffe,et al.  Cyclin D1 positive diffuse large B-cell lymphoma is a post-germinal center-type lymphoma without alterations in the CCND1 gene locus , 2011, Leukemia & lymphoma.

[12]  N. Varin‐Blank,et al.  Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma , 2010, Haematologica.

[13]  B. Coiffier,et al.  Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. , 2010, Blood.

[14]  Michael L. Wang,et al.  Ten‐year follow‐up after intense chemoimmunotherapy with Rituximab‐HyperCVAD alternating with Rituximab‐high dose methotrexate/cytarabine (R‐MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma , 2010, British journal of haematology.

[15]  Kai Fu,et al.  A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy , 2009, Clinical Cancer Research.

[16]  Yasodha Natkunam,et al.  Characterization of D-Cyclin Proteins in Hematolymphoid Neoplasms: Lack of Specificity of Cyclins D2 and D3 Expression in Lymphoma Subtypes , 2009, Modern Pathology.

[17]  J. Teruya-Feldstein,et al.  CD5 Negative, Cyclin D1-positive Diffuse Large B-cell Lymphoma (DLBCL) Presenting as Ruptured Spleen , 2009, Applied immunohistochemistry & molecular morphology : AIMM.

[18]  M. Du,et al.  Cyclin D1‐positive diffuse large B‐cell lymphoma , 2008, Histopathology.

[19]  B. Sander,et al.  A subset of CD5- diffuse large B-cell lymphomas expresses nuclear cyclin D1 with aberrations at the CCND1 locus. , 2008, American journal of clinical pathology.

[20]  G. Cattoretti,et al.  Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. , 2007, Blood.

[21]  L. Staudt,et al.  Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. , 2005, Blood.

[22]  W. Chan,et al.  Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma , 2005, Modern Pathology.

[23]  L. Pham,et al.  Inhibition of Constitutive NF-κB Activation in Mantle Cell Lymphoma B Cells Leads to Induction of Cell Cycle Arrest and Apoptosis1 , 2003, The Journal of Immunology.

[24]  Takashi Akasaka,et al.  De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. , 2002, Blood.

[25]  Ulrich Siebenlist,et al.  Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells , 2001, The Journal of experimental medicine.

[26]  Robert C Briggs,et al.  Immunohistochemical Detection of Cyclin D1 Using Optimized Conditions Is Highly Specific for Mantle Cell Lymphoma and Hairy Cell Leukemia , 2000, Modern Pathology.

[27]  H. Avet-Loiseau,et al.  Cyclin D1 expression in patients with multiple myeloma. , 2000, The hematology journal : the official journal of the European Haematology Association.